Brooklyn ImmunoTherapeutics, Inc.(NYSE Amex Equities : BTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.10%||162.16||0.7%||$1254.93m|
|MRK||Merck & Co., Inc.||1.03%||77.45||0.7%||$958.24m|
|BMY||Bristol-Myers Squibb Co.||1.54%||65.43||1.0%||$758.06m|
|LLY||Eli Lilly & Co.||1.76%||189.20||1.1%||$575.67m|
|RPRX||Royalty Pharma Plc||0.53%||41.87||0.2%||$143.72m|
|NVO||Novo Nordisk A/S||0.95%||72.19||0.1%||$62.10m|
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.